Merck drug triggers response in 24 percent of lung cancer patients – Reuters

by lowes1 on October 2, 2013

Merck drug triggers response in 24 percent of lung cancer patients
Reuters
(Reuters) – Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, showed that about a quarter of lung cancer patients responded to the treatment. Data from the trial is slated for presentation in
Merck's Immune System-Based Cancer Drug Works in 1 in 4Bloomberg
Interim Data for Merck's MK-3475, an Investigational Anti-PD-1 Immunotherapy DailyFinance

all 6 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: